Targeting autophagy to sensitive glioma to temozolomide treatment

Journal of Experimental & Clinical Cancer Research : CR
Yuanliang YanZhicheng Gong

Abstract

Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent high-grade gliomas. However, the efficacy of TMZ is often limited by the development of resistance. Recently, studies have found that TMZ treatment could induce autophagy, which contributes to therapy resistance in glioma. To enhance the benefit of TMZ in the treatment of glioblastomas, effective combination strategies are needed to sensitize glioblastoma cells to TMZ. In this regard, as autophagy could promote cell survival or autophagic cell death, modulating autophagy using a pharmacological inhibitor, such as chloroquine, or an inducer, such as rapamycin, has received considerably more attention. To understand the effectiveness of regulating autophagy in glioblastoma treatment, this review summarizes reports on glioblastoma treatments with TMZ and autophagic modulators from in vitro and in vivo studies, as well as clinical trials. Additionally, we discuss the possibility of using autophagy regulatory compounds that can sensitive TMZ treatment as a chemotherapy for glioma treatment.

References

Nov 8, 1996·The Journal of Biological Chemistry·E Ogier-DenisP Codogno
Jan 7, 2004·Journal of Neurosurgery·Takao KanzawaIsabelle M Germano
Jan 10, 2004·Cell Death and Differentiation·T KanzawaS Kondo
Feb 25, 2005·Neurosurgical Focus·Eduardo BriceñoJulio Sotelo
Oct 26, 2005·Cell Death and Differentiation·P Codogno, A J Meijer
Jul 29, 2006·Autophagy·Yasuko Kondo, Seiji Kondo
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ravi K Amaravadi, Craig B Thompson
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 17, 2008·Biochemical Society Transactions·Lorenzo GalluzziGuido Kroemer
Feb 5, 2009·Molecular Cancer Therapeutics·Vanessa MilanoJohn de Groot
Feb 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Haihao ZhuAl Charest
May 5, 2009·The Lancet Oncology·Jonathan P Knisely, Joachim M Baehring
May 9, 2009·The Journal of Clinical Investigation·María SalazarGuillermo Velasco
Jul 1, 2010·Molecular Cancer Research : MCR·Valerie VossDonat Kögel
Jan 12, 2011·Molecular Cancer Therapeutics·Sofía TorresGuillermo Velasco
Sep 29, 2011·Biochemical and Biophysical Research Communications·Yi ZhangJin-Ming Yang
Nov 30, 2011·Current Molecular Pharmacology·Jihong ZhangTracey D Bradshaw
Jan 10, 2012·Neurochemical Research·Catherine P HaarNaren L Banik
Aug 1, 2012·Oncology Letters·A CarmoM C Lopes
Oct 12, 2012·Journal of Neuro-oncology·Aditi NadkarniJann N Sarkaria
Mar 15, 2013·Nature Reviews. Molecular Cell Biology·Yosef Shiloh, Yael Ziv
Apr 3, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ilkka LiikanenAkseli Hemminki
Apr 9, 2013·Handbook of Experimental Pharmacology·Shanmugam Panneer Selvam, Besim Ogretmen
Jul 4, 2013·Free Radical Biology & Medicine·Irene Gañán-GómezGuillermo García-Manero

❮ Previous
Next ❯

Citations

Apr 4, 2016·Journal of Experimental & Clinical Cancer Research : CR·Junyang LiYouwu Fan
Dec 7, 2016·Journal of Experimental & Clinical Cancer Research : CR·Teng HuangXia He
Jun 21, 2017·International Journal of Molecular Sciences·Ying-Ying LiNiramol Savaraj
Jan 18, 2018·International Journal of Cancer. Journal International Du Cancer·Yinan ChenJinlong Shi
Nov 29, 2017·Journal of Experimental & Clinical Cancer Research : CR·Claudia AbbruzzeseMarco G Paggi
Jan 23, 2018·The FEBS Journal·Erin E MowersKay F Macleod
Sep 27, 2018·Neurologia Medico-chirurgica·Shabierjiang JiapaerMitsutoshi Nakada
May 19, 2019·Journal of Experimental & Clinical Cancer Research : CR·Silvia MatteoniMarco G Paggi
Sep 8, 2019·Molecular and Cellular Biochemistry·N G KrylovaO I Shadyro
Aug 12, 2017·Journal of Experimental & Clinical Cancer Research : CR·Maria Grazia AtzoriGrazia Graziani
Oct 17, 2019·Radiation Research·Aisling B HeeranJacintha O'Sullivan
Oct 28, 2019·Stem Cells·Malini VisweswaranArun Dharmarajan
Feb 9, 2018·Oncotarget·Zhijie XuZhicheng Gong
Jun 11, 2020·Journal of Cellular Physiology·Chunhui WangLijun Hou
Jul 31, 2016·Cellular and Molecular Neurobiology·Chenran ZhangGuohan Hu
Mar 16, 2017·Frontiers in Molecular Neuroscience·Yuanliang YanZhicheng Gong
Jun 13, 2018·The Biochemical Journal·Lindsay WildeUbaldo Martinez-Outschoorn
Apr 25, 2018·Journal of Experimental & Clinical Cancer Research : CR·Le TangZhaoyang Zeng
Mar 26, 2019·Cancer Biomarkers : Section a of Disease Markers·Xi ChenYuanliang Yan
Sep 24, 2019·Future Medicinal Chemistry·Raul OrtizJose Prados
Feb 26, 2020·Cells·Ana Laura Vieira AlvesRui Manuel Reis
May 22, 2020·Cancer Cell International·Paola PalumboBenedetta Cinque
Jul 8, 2020·Journal of Experimental & Clinical Cancer Research : CR·Jiao FengChuanyong Guo
Sep 13, 2017·Journal of Experimental & Clinical Cancer Research : CR·Alessia GarufiGabriella D'Orazi

❮ Previous
Next ❯

Methods Mentioned

BETA
Xenografts
xenograft

Clinical Trials Mentioned

NCT00486603
NCT02378532
NCT01430351

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.